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SUMMARY
Burkholderia cepacia colonizes cystic fibrosis (CF) patients. We evaluated the impact of the use of a selective medium in the rate
of B. cepacia recovery from respiratory samples of CF patients. During a 6-month period, respiratory samples were collected from
106 CF patients and cultivated on selective media including a B. cepacia selective medium. Confirmation of the identity of B. cepacia
isolates was carried out by species specific PCR and determination of genomovar status performed by a sequential PCR approach.
Results of B. cepacia isolation during this period were compared to the preceding two years, when the sample processing was
identical except for the lack of the B. cepacia selective medium. B. cepacia was isolated in 11/257 (4.2%) of the samples using the
selective medium, in contrast with the preceding two years, when it was isolated in 6/1029 samples (0.58%), p < 0.0001. Identity of
all 11 isolates was confirmed by PCR and genomovar determination was accomplished in all but one isolate. These results suggest
that the use of a selective medium increases recovery rate of B. cepacia from respiratory samples.
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INTRODUCTION
Cystic fibrosis (CF) is an inherited disease characterized by chronic
obstructive lung disease, pancreatic insufficiency and elevated chloride
levels in the sweat22,28. Cystic fibrosis patients are particularly susceptible
to infections caused by specific bacterial pathogens such as Pseudomonas
aeruginosa, Staphylococcus aureus and Haemophilus influenzae. Despite
substantial advances in the prognosis due to antimicrobial therapy and
early diagnosis, respiratory disease remain the first cause of death in
these patients8.
Burkholderia cepacia, a plant pathogen, was identified in sputum
samples from cystic fibrosis patients in the early 80s13,18,23. In some
patients, isolation of this bacteria was associated with the occurrence of
a fatal necrotizing pneumonia called B. cepacia syndrome but in the
majority of patients it caused an increase of lung function deterioration.
The inherent resistance to the majority of antimicrobial drugs and further
observations that B. cepacia strains can spread by social contact among
patients, resulted in several recommendations for new approaches on
microbiological surveillance4,25 and patient cohorting9,15. As a result,
isolation of B. cepacia in sputum from cystic fibrosis patients carries a
significant medical and psychosocial burden. Strategies for B. cepacia
infection control, however, depend on the accurate identification of this
pathogen on the microbiology laboratory.
B. cepacia is a fastidious gram-negative bacillus that can be difficult
to isolate, since it usually grows slowly when compared to other
organisms frequently found in sputum samples from CF patients, such
as P. aeruginosa. B. cepacia is also difficult to identify after isolation,
and misidentifications occur very frequently20. Although the use of
selective media is actually recommended for B. cepacia isolation, this is
not an homogenous practice among microbiology laboratories involved
in the care of cystic fibrosis patients25. Furthermore, recent taxonomic
analyses have demonstrated that B. cepacia is not an unique species, but
a complex that comprises six different genomovars or genomic species26,
and this characterization depends mainly on genomic analysis2,16,17,21,29.
In Brazil, cystic fibrosis is an underdiagnosed condition that is
primarily treated at specialized (universitary) hospitals. Since the number
of diagnosed patients is relatively small, there are not local guidelines
for microbiological practices for culturing respiratory samples obtained
from these patients, and use of selective media for B. cepacia isolation
is not a common practice among microbiology laboratories involved in
CF care. Approximately one hundred and ten cystic fibrosis patients
attend the Pediatric Pulmonology Unit of Instituto da Criança in São
Paulo, Brazil. Sputum or oropharyngeal samples of these patients are
cultured monthly or bimonthly as part of the regular follow up. During
a six month prospective study of direct detection of microorganisms in
respiratory samples by the polymerase chain reaction (PCR), samples
were also cultured in a B. cepacia selective medium.

SILVA FILHO, L.V.F.; VELLOSO, L.F.; BENTO, C.N.O.; GYTIN, E.; TATENO, A.F.; LEVI, J.E.; RODRIGUES, J.C. & RAMOS, S.R.T.S. - Use of selective medium for Burkholderia
cepacia isolation in respiratory samples from cystic fibrosis patients. Rev. Inst. Med. trop. S. Paulo, 44(4):203-208, 2002.
The aim of this study was to compare the rate of isolation of B.
cepacia during this period with the rate of isolation in the previous two
years, when sample processing was identical, except for the lack of the
B. cepacia selective medium. Confirmation of the identity of B. cepacia
isolates was also examined by species specific PCR2, and genomovar
determination was attempted by a PCR approach described by WHITBY
et al.29.
PATIENTS AND METHODS
A total of 106 cystic fibrosis patients (sex: 53M:53F; age: 9m-19y,
mean age = 9.77 ± 4.83 years) being treated at the Pediatric Pulmonology
Unit of Instituto da Criança of University of São Paulo were studied
from September 2000 to April 2001. Diagnosis of CF was based on
clinical symptoms and two positive sweat tests or identification of two
mutations by genetic analysis, according to international guidelines22.
SAMPLES: During the period of study, samples of sputum or
oropharyngeal swabs from CF patients were collected on each patient
visit. Sputum samples were collected directly by expectoration in a
sterilized plastic receptacle, and throat swabs were collected by direct
friction of a sterile cotton swab in the posterior pharynx, if possible after
coughing and with concomitant use of a tongue depressor. Sputum
samples were initially processed as described by WONG et al.30. Briefly,
an equal volume of a sterile solution of dithithreitol (DTT) 50 µg/mL in
phosphate buffered saline with 0.1% of gelatin was added to the sputum
samples and after 30 minutes homogenized by vortexing. Oropharyngeal
swabs were kept on transport medium (modified Stuart’s bacterial
transport medium, Beckton Dickinson, USA) until delivery to the
microbiology laboratory within a short period of time (up to four hours).
Written informed consent was obtained from the parents. The Ethical
Committee of the Institution approved the study.
CULTURE TECHNIQUES: The samples were cultivated on blood
agar (Columbia Agar – Oxoid), chocolate agar (GC Agar – Biobrás, São
Paulo, Brazil), MacConkey agar (MacConkey Agar – Merck) and B.
cepacia selective medium (Burkholderia cepacia medium – Oxoid),
incubated at 36 ± 1 °C for a period of 18 to 48 hours. Bacterial
identification was performed with Vitek system (bioMérieux Vitek Inc.,
St. Louis, Mo), using Gram-negative – GNI and Gram-positive – GPI
cards, and additional biochemical tests for bacterial identification
whenever necessary. Results were recorded after 24 h of incubation at
37 oC. All isolates of B. cepacia were transferred to tryptic soy broth
(Tryptic Soy Broth - Merck) with 50% glycerol and stored in a –80 °C
freezer.
The results of culture of respiratory samples obtained from the same
group of patients in the preceding two years were obtained by
retrospective analysis of medical records. During this period, the sample
processing was identical, except for the initial processing of sputum
samples (addition of dithiothreitol) and the lack of B. cepacia selective
medium.
DNA EXTRACTION: DNA of B. cepacia isolates was extracted
by the Proteinase K - Phenol Chloroform method24. Bacterial colonies
were suspended in 500 µL of a solution consisting of 200 µg/mL
Proteinase K (GIBCO-BRL Gaithesburg, FL, USA); Tris 50 mM pH =
8.0; SDS 0.5% and incubated at 56 oC for 1 h, then boiled for 10 minutes.
This was followed by two steps of organic extraction with Phenol-
Chloroform (vol:vol) and DNA precipitation with 2.5 volumes of cold
ethanol and 0.1 volume of sodium acetate (3M, pH = 5.2). After
centrifugation, the pellet was dried and solubilized in sterile water, and
DNA was quantified in a UV spectrophotometer (UltroSpec 3000 UV/
Visible Spectrophotometer - Pharmacia, Uppsala, Sweden).
SPECIES SPECIFIC PCR: Species specific PCR was performed
as described by BAUERNFEIND et al.2, using primers Eub-16-1 (AGR
GTT YGA TYM TGG CTC AG) and CeMuVi-16-2457 (CCG RCT GTA
TTA GAG CCA) targeting a 463 base pair segment of the 16S ribosomal
DNA of B. cepacia. Reactions were done in a final volume of 25 µL
containing 100 ng of template DNA, 0.4 µM of each primer, 2 mM of
MgCl2, 10 mM Tris HCl (pH 8.0), 50 mM KCl, 250 µM of dNTPs and
1U of Taq DNA polymerase (GIBCO-BRL Gaithesburg, FL, USA).
Amplification was carried out using Mastercycler gradient thermocycler
(Eppendorf) with an initial denaturation step of 94 oC for 4 minutes and
30 cycles of 94 oC for 1 minute, 56 oC for 1 minute and 72 oC for 1
minute followed by additional 7 minutes at 72 oC. Following
amplification, PCR products were visualized by electrophoresis in 1.5%
agarose gel stained with ethidium bromide 0.5 mg/mL, with an UV
transilluminator. A negative control (sample with no DNA added) was
included in all PCR reactions.
PCR FOR GENOMOVAR DETERMINATION: Determination
of genomovar status of B. cepacia isolates was performed according to
the protocol described by WHITBY et al. 29, using primers G1-G2, SPR3
and SPR4. Isolates were submitted to three separate PCR reactions with
primers G1-G2, SPR3-G1 and SPR4-G1, and genomovar status was
defined according to the algorithm shown in Fig. 1. PCR reactions were
performed in 25 µL mixtures containing 200 ng of template DNA, 2
mM of MgCl2, 0.8 µM of each primer, 10 mM Tris HCl (pH 8.0), 50
mM KCl, 200 µM of dNTPs and 1.25U of Taq DNA polymerase
(GIBCO-BRL Gaithesburg, FL, USA). Amplification was carried out
using Mastercycler gradient thermocycler (Eppendorf) with an initial
denaturation step of 95 oC for 5 minutes and 30 cycles of 94 oC for 45
seconds, 66 oC for 45 s and 72 oC for 2 minutes followed by a final
extension step at 72 oC for 10 minutes. Following amplification, PCR
products were visualized by electrophoresis in 0.8% agarose gel stained
with ethidium bromide 0.5 mg/mL, with an UV transilluminator. A
negative control (sample with no DNA added) was included in all PCR
reactions.
Fig. 1 - PCR algorithm to identify the species and genomovars of the B. cepacia complex.
Reproduced from WHITBY et al.29.
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STATISTICAL ANALYSIS: The results of B. cepacia isolation
during the six month period were compared to the results of preceding
two years, when the sample processing was identical except for the lack
of a B. cepacia selective media. Comparisons between the results of the
two periods used 2 test or two-tailed Fisher exact test, and a p value <
0.05 was considered significant.
RESULTS
During the six month study period, a total of 257 samples were
cultured. B. cepacia was isolated in 11/257 (4.2%) of the samples using
the B. cepacia selective medium. Cultures were obtained from 9 sputum
samples and two oropharyngeal swabs, from 8 patients aged 11 months
to 17 years old. In the two years preceding the start of the study, B.
cepacia was isolated in 6/1029 samples (0.58%), from 5 patients aged 7
to 16 years old. The difference in the rate of isolation among the two
periods, 11/257 (4.2%) versus 6/1029 (0.6%) was statistically significant
(two-tailed Fisher exact test, p < 0.0001), Fig. 2. However, the number
of patients characterized as colonized by B. cepacia (i.e., with at least
one sample positive for the bacterium) was not significantly different
when the two periods were compared (8/106 (7.5%) versus 5/106 (4.7%),
2 test: p = 0.39).
The identity of the 11 isolates of B. cepacia was confirmed by species
specific PCR, with all isolates tested resulting in a 463 bp amplicon
resultant of amplification of the 16S ribosomal DNA of B. cepacia, as
partially shown in Fig. 3.
The application of the PCR protocol for B. cepacia genomovar
determination classified two strains as Burkholderia vietnamiensis, two
strains as Burkholderia multivorans and 4 strains as belonging to
genomovars I or III, as shown in Table 1 and illustrated in Fig. 4. PCR
reactions resulted in the amplification of DNA fragments of
approximately 1.3 kb in at least one of the combination of the three
primers in all but two samples, which were assigned as B. vietnamiensis.
Table 1
PCR results of B. cepacia complex genomovar determination, using primers G1, G2, SPR3 and SPR4, as described by WHITBY et al.29. Patient names are
indicated by assorted initials. PCR results are expressed: +, positive PCR; -, negative PCR
PRIMER PAIRS
Sample Date of Patient G1/G2 SPR3/G1 SPR4/G1 Genomovar /
isolation Subspecies
6 9/27/2000 SL - - - B. vietnamiensis
21 10/5/2000 ABL - + - B. multivorans
106 12/18/2000 ABL - + - B. multivorans
29 10/16/2000 CLO + + - Genomovar III (or I)
176 2/7/2001 CLO + + - Genomovar III (or I)
55 10/30/2000 OCR + + - Genomovar III (or I)
130 1/10/2001 THC + + - Genomovar III (or I)
157 1/24/2001 THC + + - Genomovar III (or I)
137 1/15/2001 NCC + + - Genomovar III (or I)
177 2/7/2001 SFRV + - - Undetermined
220 3/14/2001 SAG - - - B. vietnamiensis
Fig. 3 - Species specific PCR of representative B. cepacia strains with primers Eub-16-1/
CeMuVi-16-2457.
Lane 1: B. cepacia strain obtained from the microbiology laboratory repository. Lanes 2 to
10: nine representative strains of B. cepacia isolated during the six month study period. Lane
11: negative control (no DNA added). M: molecular weight marker (100 bp ladder, Pharmacia,
Upsalla, Sweden).
Fig. 2 - Graphical representation of the rate of isolation of B. cepacia in the two periods
studied. * two-tailed Fisher exact test: p < 0.0001.
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We didn’t observe PCR products using the primers G1-SPR4 in any of
the strains tested (Table 1), and therefore we did not identify strains of
B. stabilis or B. cepacia genomovar I. The genomovar status of one
isolate could not be determined, as it didn’t result in PCR products of
the expected size with primer pair G1-SPR3 while showed positive result
with primer pair G1-G2, an unexpected event.
DISCUSSION
B. cepacia is a microorganism that has great significance in cystic
fibrosis. Since its recognition as an infecting agent in CF patients in the
mid 80s, much have been learned about its importance, transmission
and clinical impact, but several questions remain to be answered. The
isolation of this organism in respiratory secretions of CF patients still
carry a severe psychosocial burden, arising from the precautions to
minimize person-to-person transmission and to the increased rates of
morbidity and mortality in this patient population15.
Pseudomonas cepacia was originally described by Burkholder in
1950 as the causative agent of bacterial rot of onion bulbs. In 1992, P.
cepacia was transferred to the new genus Burkholderia, which currently
include 22 bacterial species7. Several additional modifications in the
taxonomy of B. cepacia have occurred in the last decade, with the
recognition of marked heterogeneity among B. cepacia strains isolated
from different echological niches. B. cepacia was classified as a complex,
comprising at least five different genomic species or genomovars26. B.
cepacia genomovar V was identified as the previously described species
B. vietnamiensis7 and the name B. multivorans was proposed for strains
belonging to the genomovar II. B. cepacia genomovar IV was
subsequently classified as B. stabilis27. Recent taxonomic studies
identified more three members of B. cepacia complex, B. cepacia
genomovar VI, B. ambifaria and B. pyrrocinia1,5,6.
Clinical management of respiratory infections in CF patients rely on
the identification of organisms cultured from respiratory specimens such
as sputum, oropharyngeal swabs or bronchoalveolar lavage samples, but
this apparently simple procedure may not be straightforward.
Identification of B. cepacia can be problematic and misidentifications
may be relatively common. As many as 20% of isolates sent to reference
laboratories identified as B. cepacia may be misidentified20. Therefore,
the use of a selective media that take advantage of the species broad
antibiotic resistance is a critical first step in sample processing.
A comparison of three media was performed by HENRY et al.11,
reporting superiority of BCSA (B. cepacia selective agar) to OFPBL
and PCA (P. cepacia medium) in terms of rapidity and quality of recovery
of B. cepacia complex organisms from CF respiratory specimens, while
inhibiting the growth of other organisms. The above mentioned medium
(BCSA), however, is not indicated for isolation of environmental B.
cepacia isolates, due to low specificity/sensitivity.
We utilized a different medium, named B. cepacia medium (Oxoid),
mainly indicated for the isolation and identification of B. cepacia from
respiratory secretions of CF patients. As expected, a significant difference
of isolation rates of B. cepacia strains was observed among the two periods
analyzed (with and without the use of selective medium), which was
probably derived from the discriminating properties of the B. cepacia
selective medium. Although there was a significant difference in the rate
of B. cepacia isolation, the use of the selective medium did not contribute
to identification of a significant broader patient population colonized with
B. cepacia, but isolation of B. cepacia was observed in younger patients
and in two oropharyngeal swabs samples. The impact of the use of
dithiothreitol (DTT) as a solubilizing agent in culture results was previously
assessed by HAMMERSCHLAG et al., who showed that the substance
may interfere in the isolation rate of H. influenzae only when high
concentrations were used10. Although this aspect was not specifically
addressed in the present work, it seems unlikely that the use of DTT as
part of initial sample processing had some influence in the observed results.
Although there are recommendations for specific microbiological
practices when culturing samples from CF patients, they are not
universally adopted, even in more specialized laboratories. The situation
in Brazil is quite different, since there are few specialized centers for CF
care and there is no information or consensus for the microbiology
practices used for culturing respiratory samples obtained from CF
patients.
The use of PCR for the identification of B. cepacia strains was
described by a number of authors3,14, but the taxonomic changing of the
Burkholderia genus have posed new potential caveats associated with
some primer pairs described, such as cross reactivity with non-B.cepacia
complex organisms or poor specificity for the identification of some of
the species16,19. To date, the only described primer pairs that are supposed
to identify all members of the B. cepacia complex are those described
by BAUERNFEIND et al.2, Eub-16-1/ CeMuVi-16-2457, which identify
genomovars I, III, B. multivorans, B. vietnamiensis and B. stabilis, and
primers BCR1/BCR2, described by MAHENTHIRALINGAM et al.17,
which are able to identify all members of the B. cepacia complex,
including the very recently described B. cepacia genomovar VI and
genomovar VII (B. ambifaria)17,19.
We decided to use the primer pair described by BAUERNFEIND et
al., since it is currently being tested by our group for direct detection of
Fig. 4 - PCR for B. cepacia complex genomovar determination, as described by WHITBY et
al. 29. Expected size of amplicons for each primer pair: 1.3 kb.
Each lane represents PCR products obtained with the primer pair indicated on the top; sample
29 was assigned as B. cepacia genomovar III (or I); sample 21 as B. multivorans and sample
6 as B. vietnamiensis. M: molecular weight marker (100 bp ladder, Pharmacia, Upsalla,
Sweden).
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B. cepacia strains in respiratory samples from CF patients. Our PCR
results with this primer pair confirmed the identity of all the eleven B.
cepacia strains isolated with the selective medium. This primer pair was
also tested in PCR reactions with DNA of other bacterial species
frequently found in the sputum of CF patients (P. aeruginosa, S. aureus,
H. influenzae, S. maltophilia), and didn’t result in any visible PCR product
(data not shown).
The knowledge of B. cepacia complex genomovar species
responsible for respiratory infections in CF patients is extremely
important for appropriate segregation and grouping of CF patients into
cohorts15,19. Although there are now recent described phenotypic tests
for genomovar determination, it is still not possible to identify all
genomovars based on this approach12. Several strategies have been
proposed for the identification of genomovars using molecular biology
techniques, and the method described by WHITBY et al.29 was chosen
because of its simplicity, although it is not able to differentiate
genomovars I and III. Since CF patients are predominantly colonized by
genomovar III and B. multivorans16,19,26, this limitation doesn’t constitute
a significant pitfall. The results obtained with the PCR approach using
primers G1, G2, SPR3 and SPR4 confirmed this predominance of
genomovar III (most likely) among our CF patients, although we found
the same proportion of patients colonized by B. multivorans and B.
vietnamiensis (two patients colonized with each species). Three patients
have two B. cepacia positive cultures, obtained on different dates; none
of them, however, presented different genomovars.
In summary, our results confirmed the importance of the use of a
selective medium for B. cepacia isolation when culturing respiratory
samples from cystic fibrosis patients. We have also confirmed the identity
of all isolates of B. cepacia by species specific PCR and further
characterized these isolates by genomovar status, obtaining results similar
to those described on other CF specialized Centers.
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RESUMO
Uso de meio seletivo para identificação de cepas de Burkholderia
cepacia em amostras de trato respiratório de pacientes portadores
de fibrose cística
A Burkholderia cepacia coloniza os pacientes portadores de fibrose
cística (FC). Avaliamos o impacto do uso de um meio seletivo no
isolamento de B. cepacia em amostras de secreção respiratória de
pacientes portadores de FC. Durante um período de 6 meses, amostras
de trato respiratório foram colhidas de 106 pacientes com FC e cultivadas
em meios seletivos incluindo um meio para isolamento de B. cepacia. A
identidade das cepas de B. cepacia foi confirmada através de PCR espécie
específica e a determinação do genomovar ou subespécie realizada através
de reações seqüenciais de PCR. Os resultados de isolamento de B. cepacia
durante este período foram comparados com os dois anos precedentes,
quando o processamento das amostras era idêntico, exceto pela utilização
do meio seletivo para B. cepacia. B. cepacia foi isolada em 11/257 (4,2%)
amostras usando o meio seletivo, e em apenas 6/1029 (0,58%) nos dois
anos precedentes (p < 0,0001). A identidade destas 11 cepas foi
confirmada e a determinação do genomovar obtida em 10/11. Estes
resultados sugerem que o uso do meio seletivo aumenta a freqüência de
isolamento de B. cepacia em amostras de trato respiratório de pacientes
portadores de FC.
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